跳至主要内容
临床试验/NL-OMON53197
NL-OMON53197招募中不适用

Implementation of a remote home monitoring program for patients with a mild acute pancreatitis - A single center feasibility study (INTERACT) - INTERACT

Rijnstate Ziekenhuis0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Acute pancreatitis according to the revised Atlanta criteria for pancreatiti.
  • Which is at least 2 of the following 3 criteria:
  • - Abdominal pain consistent with acute pancreatitis
  • - Serum lipase >= 3x upper limit normal (> 159 U/l)
  • - Typical pancreatic abnormalities on imaging (ultrasound, CT or MRI)
  • First episode of acute pancreatitis or a prior pancreatitis more than 3
  • Age >=18 years, both men and women
  • Able and willing to provide written informed consent in Dutch
  • In possession of a working (smart)phone on which patient can be reached for
  • the duration of participation (30 days)
  • <=1 SIRS criteria:
  • * temperature < 36*C or > 38*C
  • * heart rate > 90/min
  • * respiratory rate >20/min
  • * leucocytes < 4x/109l or > 12x109/l
  • Serum CRP <= 150 mg/l on day of discharge and with a decreasing trend in days
  • Pain score (NRS) <=6 with or without the use of pain medication
  • Adequate intake of oral food and fluids (= >=2 small meals and >=1L fluids per
  • Stable serum creatinine and Ringer's lactate infusion reduced to <1L/24 hours
  • Independent in performing general daily life activities

排除标准

  • Chronic pancreatitis according to M-ANNHEIM criteria.
  • Acute cholangitis
  • Endoscopic retrograde cholangiopancreatography within the first 24 hours of
  • MEWS (Modified Early Warning Score) >=6 or in need of ICU admission
  • Living in an institution (e.g. psychiatric ward or nursing home), or the
  • absence of a household member capable of alerting the hospital in case of an
  • Known sensitivity to medical adhesives
  • Known pregnancy
  • Have one or more of the following comorbidities:
  • - Heart failure (NYHA class III or IV)
  • - COPD (Gold III-IV)
  • - Kidney disease (>G3b) and/or kidney replacement therapy
  • - Currently undergoing oncological treatment
  • - Use of immunosuppressants
  • - Dysregulated or poorly controlled insulin dependent diabetes
  • - Morbid obesity (BMI>35 kg/m2)
  • - Implantable Cardioverter Defibrillator (ICD) or Pacemaker

研究者

发起方
Rijnstate Ziekenhuis

相似试验